LONDON, July 3, 2026, 22:01 BST
- Tate & Lyle finished at 556.50p/557.00p post-close in London, gaining 3.00p. The cash offer stands at 595p a share.
- The 13.2p final dividend has gone ex-dividend. The company could still pay a 6.8p interim dividend under the allowed payout plan.
- The fee pool of up to £163 million comes close to Tate & Lyle’s FY26 free cash flow, which stands at £164 million.
Tate & Lyle PLC (LON:TATE) is trading more like a bond than a typical food ingredient play right now. Hargreaves Lansdown priced the stock at 556.50p/557.00p at the London close, up 3.00p. Sharecast had the FTSE 250 (INDEXFTSE:MCX) closing 0.52% higher, with the UK food producers and processors index up 0.49%.
This isn’t because of the day’s price action. Tate & Lyle and Ingredion Incorporated NYSE:INGR said Friday the scheme document is now with shareholders. Court and general meetings are scheduled for July 28. Completion could land in the back half of 2027 if shareholders, regulators and the court sign off.
The buy quote was at 557.00p, leaving a 38p gap to the 595p cash offer, or around 6.8%. The 13.2p final dividend went ex-div June 18, with the record date June 19 and payout on July 31. New buyers now are mostly focused on the cash portion and a potential 6.8p interim dividend.
| Tate & Lyle deal maths | Pence per share | Gross gap vs 557.00p buy quote |
|---|---|---|
| Cash on the table | 595.0p | 38.0p / 6.8% |
| Cash and maybe leftover interim dividend | 601.8p | 44.8p / 8.0% |
| 2026 final payout | 13.2p | Already ex-dividend |
The spread here is notable given how long the timeline runs. The RNS gives a long stop date of Dec. 8, 2027, and the deal announcement points out the scheme depends mainly on material antitrust conditions.
The stock stayed roughly in line with its peers. This deal now looks like a bet on how the market values the time lag, antitrust questions, and the drag from letting capital sit until 2027, not another quick pop from a raised bid.
| July 3 market screen | Latest quoted level | Daily move |
|---|---|---|
| Tate & Lyle showing bid at 556.50p, ask at 557.00p | 556.50p / 557.00p | up 3.00p, or 0.54% |
| FTSE 250 last trade | 23,538.80 | added 0.52% |
| Food Producers & Processors sector | 7,406.34 | gained 0.49% |
The latest number is the fee hit. The Times reported advisers, lawyers, banks, and PR firms could collect as much as £163 million from the deal. Tate & Lyle could pay up to £64.2 million, while Ingredion could owe as much as $132.3 million.
The total fee pool works out to about 6.0% of the £2.7 billion cash offer equity value. Tate & Lyle’s own fee estimate is about 39% of its FY26 free cash flow of £164 million. The full fee pool is close to one year’s free cash flow.
| Fee and flow check | Amount | Comparison |
|---|---|---|
| Cash equity offer comes in at | £2.7 bln | Base |
| Fee pool reported | Up to £163 mln | Equals 6.0% of the cash equity |
| Tate & Lyle deal fees reported | Up to £64.2 mln | 39% of projected FY26 free cash flow |
| Tate & Lyle expected FY26 free cash flow | £164 mln | Base |
The fee bill leaves the 595p cash offer unchanged for shareholders. But it spells out how much it costs just to close this slow-moving cross-border deal. Ordinary shareholders now have to weigh if it’s worth sitting tight for a spread of 38p to 44.8p.
The June 8 Rule 2.7 statement put the 595p cash offer at roughly £2.7 billion for Tate & Lyle’s current and potential share capital, pointing to an enterprise value of £3.7 billion. If including allowed dividends up to 20p, the total goes to 615p per share—putting equity at about £2.8 billion and enterprise value at £3.8 billion.
Ingredion is pitching the deal on scale and savings. Both companies say the merged business should see $9.9 billion in revenue and $1.8 billion adjusted EBITDA. Annual run-rate cost synergies are expected to reach $130 million by 2030. Achieving those savings will require $175 million of one-time costs.
Tate chair David Hearn called the deal an “attractive opportunity for shareholders to crystallise value in cash.” Ingredion chair and CEO Jim Zallie said the companies could form a “global leader in ingredient solutions.” Tate & Lyle
Tate & Lyle’s results shed some light on why the board stuck with cash. Pro forma revenue and adjusted EBITDA for FY26 both slipped 3%. CEO Nick Hampton said the priority now is getting the “new business pipeline” to deliver “volume-led growth.” Tate & Lyle
Key dates are approaching: July 10 is the cut-off for the dividend reinvestment plan mandate. Voting instructions for the scheme must be in by July 23 and 24. Shareholders meet on July 28 and the final dividend will be paid July 31.
